The Coronavirus pandemic has forced medical researchers, drug makers, and vaccine developers to move fast, without sacrificing safety. The drug development and approval process takes time to balance the safety and efficacy of therapies while minimizing public health risks. But in the quest to understand the deadly virus that causes COVID-19 and find a cure, scientists have accelerated their research methods and clinical trials. As a consequence, policymakers, public health officials and health care providers are getting access to medical research and potential treatments much faster than before the outbreak. As the scientific ecosystem changes in response to the pandemic, how might it re-shape medical research, drug development and health care?

Join POLITICO on Wednesday, June 24, for a deep-dive conversation on the future of science in a post-Covid-19 world. Explore what lessons can be learned to accelerate medical research outside of the coronavirus, what can be done to minimize misinformation from flawed or inaccurate scientific studies published during a public health emergency and how can newly developed drugs and vaccines be distributed equitably.

Agenda
 8:00 AM — Doors Open
 8:25 AM — POLITICO Opening Remarks

 8:30 AM — Sponsored Segment

    Fernand Amandi, Principal, Bendixen-Amandi
    Yanna Krupnikov, Associate Professor, Political Science, Stony          Brook University
    Moderator: Sam Gill, Senior Vice President and Chief Program          Officer, Knight Foundation

 8:45 AM — POLITICO Editorial Panel Conversation

    Caroline Bye, Managing Director, Morning Consult

    Matt Dailer, Deputy Political Director, RNC

    Kristal Knight, Political Director, Priorities USA

    Costas Panagopoulos, PhD, Department Chair and Professor of

    Political Science, Northeastern University

    Moderator: Peter Canellos, Editor-at-large, POLITICO